Cell2Cure has January 2024 received a significant equity investment from Endeavour Cell ApS, to further develop our collaboration.
Endeavour Cells will own 51% of the company. In addition to the invested capital the collaboration with Endeavor Cells includes milestone payments and potential continued financing of Cell2Cure’s activities within a 5-year time frame.
This collaboration will further consolidate Cell2Cure and strengthen the technological, clinical and commercial development of our very promising stem cell treatment technology.
The overall goal for Cell2Cure is to establish stem cells as a new treatment option for several disease indications for the benefit of the patients and the society.